Evidence map›Paper›PMID 30099088›Full record

ArticleToxicology in vitro : an international journal published in association with BIBRA2018

Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.

Varvara Gouliarmou, Alfonso Maria Lostia, Sandra Coecke, Camilla Bernasconi, Jos Bessems, Jean Lou Dorne, Stephen Ferguson, Emanuela Testai, Ursula Gundert Remy, J Brian Houston and 9 more

Open access · greenAbstract read
In one paragraph

Article in Toxicology in vitro : an international journal published in association with BIBRA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Identifying xenobiotic metabolites withFrontiers in toxicology · 2023
    Article
  11. Review
  12. Article
  13. Metabolic profiling andToxicology reports · 2022
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 7 countries.

Varvara GouliarmouEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Alfonso Maria LostiaEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Sandra CoeckeEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy. Electronic address: sandra.coecke@ec.europa.eu.
Camilla BernasconiEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Jos BessemsEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Jean Lou DorneEuropean Food Safety Authority, Via Carlo Magno, 1A, 43126 Parma, PR, Italy.
Stephen FergusonUS National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC 27709, USA.
Emanuela TestaiIstituto Superiore di Sanità, Environment & Health Dept., Viale Regina Elena 299, 00161 Rome, Italy.
Ursula Gundert RemyInstitute for Clinical Pharmacology and Toxicology, Charité, Universitätsmedizin Berlin, Charitéplatz 1, D-110117 Berlin, Germany.
J Brian HoustonManchester Pharmacy School, University of Manchester, Manchester M13 9PT, UK.
Mario MonshouwerJanssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Andy NongComputational Toxicology Laboratory, Exposure and Biomonitoring Division, Health Canada - Environmental Health Science and Research Bureau, 50 Colombine Dwy, Environmental Health Centre, Tunney's Pasture AL:0800C, Ottawa, ON K1A 0K9, Canada.
Olavi PelkonenResearch Unit of Biomedicine/Pharmacology and Toxicology, Faculty of Medicine, Aapistie 5 B, FIN-90014, University of Oulu, Finland.
Siegfried MorathEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Barbara A WetmoreU.S. EPA, Office of Research and Development, National Exposure Research Laboratory, 109 T.W. Alexander Drive, MD E243-04, Research Triangle Park, NC 27711, USA.
Andrew WorthEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Ugo ZanelliDiscovery DMPK, Merck KGaA Darmstadt, Germany.
Maria Chiara ZorzoliEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Maurice WhelanEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi 2749, 21027 Ispra, VA, Italy.
Joint Research Centre · ITCharité - Universitätsmedizin Berlin · DEEnvironmental Protection Agency · USEuropean Food Safety Authority · ITHealth Canada · CAIstituto Superiore di Sanità · ITJanssen (Belgium) · BEMerck (Germany) · DENational Institute of Environmental Health Sciences · USUniversity of Manchester · GBUniversity of Oulu · FI

Funding

Biomolecular Screening and Alternative Approaches for the National Toxicology ProgramZIAES103318 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CASEY, WARREN · 2016 to 2021
$25.0M
Intramural EPA EPA999999
6 · The paper itself

Abstract

Hepatic metabolic clearance is one of the most important factors driving the overall kinetics of chemicals including substances used in various product categories such as pesticides, biocides, pharmaceuticals, and cosmetics. A large number of in vitro systems from purified isozymes and subcellular organelles to hepatocytes in simple cultures and in complex scaffold setups are available for measuring hepatic metabolic clearance for different applications. However, there is currently no approach for systematically characterising and comparing these in vitro methods in terms of their design, applicability and performance. To address this, existing knowledge in the field of in vitro human hepatic metabolic clearance methods was gathered and analysed in order to establish a framework to systematically characterise methods based on a set of relevant components. An analogous framework would be also applicable for non-human in vitro systems. The components are associated with the biological test systems used (e.g. subcellular or cells), the in vitro method (e.g. number of cells, test item solubility), related analytical techniques, data interpretation methods (based on substrate depletion/metabolite formation), and performance assessments (precision and accuracy of clearance measurements). To facilitate the regulatory acceptance of this class of methods, it is intended that the framework provide the basis of harmonisation work within the OECD.

Indexed as

HumansLiverMetabolic Clearance RateModels, BiologicalADMEChemical risk assessmentIn vitro hepatic metabolic clearanceNew approach methodologyToxicokinetics

Identifiers

PMID30099088
PMCPMC10288526
OpenAlexW2886557322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.